Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials

Image caption: A unique once-a-day pill to treat ALS has been approved for ongoing clinical trials. Image credit: Depositphotos. Article by Paul McClure. New Atlas – May 29, 2024. Source: Spinogenix.

Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, affects nerve cells in the brain and spinal cord, called motor neurons, that control voluntary muscle movements like walking, talking, and breathing. As the neurons die and can’t send messages to the muscles, loss of muscle control worsens over time and is eventually fatal. […]

Click here to view original web page at newatlas.com